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Abstract
Background: Vitamin D transcriptional effects were linked to tumor growth control, however, the hormone targets
were determined in cell cultures exposed to supra physiological concentrations of 1,25(OH)2D3 (50-100nM). Our aim
was to evaluate the transcriptional effects of 1,25(OH)2D3 in a more physiological model of breast cancer, consisting
of fresh tumor slices exposed to 1,25(OH)2D3 at concentrations that can be attained in vivo.
Methods: Tumor samples from post-menopausal breast cancer patients were sliced and cultured for 24 hours with
or without 1,25(OH)2D3 0.5nM or 100nM. Gene expression was analyzed by microarray (SAM paired analysis,
FDR≤0.1) or RT-qPCR (p≤0.05, Friedman/Wilcoxon test). Expression of candidate genes was then evaluated in
mammary epithelial/breast cancer lineages and cancer associated fibroblasts (CAFs), exposed or not to 1,25(OH)2D3
0.5nM, using RT-qPCR, western blot or immunocytochemistry.
Results: 1,25(OH)2D3 0.5nM or 100nM effects were evaluated in five tumor samples by microarray and seven and
136 genes, respectively, were up-regulated. There was an enrichment of genes containing transcription factor
binding sites for the vitamin D receptor (VDR) in samples exposed to 1,25(OH)2D3 near physiological concentration.
Genes up-modulated by both 1,25(OH)2D3 concentrations were CYP24A1, DPP4, CA2, EFTUD1, TKTL1, KCNK3.
Expression of candidate genes was subsequently evaluated in another 16 samples by RT-qPCR and up-regulation of
CYP24A1, DPP4 and CA2 by 1,25(OH)2D3 was confirmed. To evaluate whether the transcripitonal targets of 1,25(OH)
2D3 0.5nM were restricted to the epithelial or stromal compartments, gene expression was examined in HB4A, C5.4,
SKBR3, MDA-MB231, MCF-7 lineages and CAFs, using RT-qPCR. In epithelial cells, there was a clear induction of
CYP24A1, CA2, CD14 and IL1RL1. In fibroblasts, in addition to CYP24A1 induction, there was a trend towards up-
regulation of CA2, IL1RL1, and DPP4. A higher protein expression of CD14 in epithelial cells and CA2 and DPP4 in
CAFs exposed to 1,25(OH)2D3 0.5nM was detected.
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Conclusions: In breast cancer specimens a short period of 1,25(OH)2D3 exposure at near physiological
concentration modestly activates the hormone transcriptional pathway. Induction of CYP24A1, CA2, DPP4, IL1RL1
expression appears to reflect 1,25(OH)2D3 effects in epithelial as well as stromal cells, however, induction of CD14
expression is likely restricted to the epithelial compartment.
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Background
Epidemiological data indicates higher incidence and
mortality rates from breast cancer in low latitude re-
gions. Among the mechanisms suggested for a relation-
ship between sunlight and cancer is the genesis of
vitamin D in the skin, resulting from the UV light ac-
tion. In accordance with this hypothesis, there is evi-
dence that lower 25(OH)D3 [1-5] and 1,25(OH)2D3 [6,7]
serum concentrations are encountered in patients with
breast cancer, as compared with women without cancer,
as well as in patients with advanced or metastatic disease
in comparison with those with early-stage disease [8,9].
In addition, 25(OH)D3 deficiency at diagnosis was re-
lated with poor prognosis, evaluated as metastasis-free
and overall survival [10].
In human breast xenografts established in immunossupressed
mice 1,25(OH)2D3 exerts growth inhibitory effects, and in
mouse mammary organ culture exposed to chemical car-
cinogens, both 25(OH)D3 and 1,25(OH)2D3 mediate pre-
ventive effects [11-13]. However, the chemopreventive
effect of vitamin D is still controversial, as supplementa-
tion trials on vitamin D3 and colon or breast cancer inci-
dence have been inconsistent [14,15]. One critical issue is
that the appropriate supplementation dose for cancer pre-
vention trials was not well established [16]. On the other
hand, clinical studies point to a clinical benefit for 1,25
(OH)2D3 (or analogues) alone or in combination with
chemotherapy in the treatment of hormone refractory
prostate cancer and breast cancer skin lesions [17,18].
However, concerns about hypercalcemic side effects limit
the dose of 1,25(OH)2D3 (or analogues) that can be safely
administered in vivo.
Phase I clinical studies indicate that subcutaneous doses
of calcitriol given every other day result in peak 1,25(OH)
2D3 serum concentration of 0.25-0.75 nM [19] while
weekly pulses of oral calcitriol allow higher dose adminis-
tration and peak serum concentrations of 1–15 nM [20].
Although these vitamin D concentrations represent about
1.3-83 times the upper limit of physiologic serum levels,
they are well below the concentrations (10-100nM) typic-
ally used to investigate hormone actions in cell culture
studies. At these concentrations, 1,25(OH)2D3 exerts
antiproliferative and pro apoptotic effects [21] and
modulates angiogenesis [22,23], invasion and metastasis
[24,25]. Among the downstream targets of the hormone
are cyclin dependent kinase inhibitors as p21WAF1/CIP1 and
p27KIP1; growth factors, receptors and associated proteins
as TGFβ, TGFβ receptors and insulin-like growth factor
binding protein-3 (IGFBP-3) [26-31]. In addition, gene ex-
pression profiling of breast cancer cell lines MCF7 and
MDA-MB-231 have identified many potential 1,25(OH)
2D3 target genes, [24] but again, these studies were
conducted with supra physiological concentrations of
calcitriol (50-100nM). Furthermore, experiments in cell
lines do not reflect the complex array of interactions
among malignant and stromal cells, secreted factors and
extracellular matrix proteins taking place in the tumor
microenvironment, which also modulate the hormone
actions.
Although the majority of human breast cancers ex-
press vitamin D receptors (VDR) [7,32,33], there have
been no demonstrations that 1,25(OH)2D3 modulates
gene expression in human breast cancer samples. To ad-
dress this research gap, a physiologically relevant in vitro
model to study 1,25(OH)2D3 actions, represented by
short term culture of fresh breast cancer tissue slices,
which maintain the epithelial mesenchymal relationship
and preserve tissue morphology and proliferation rate,
was established [25,34,35]. With this organotypic culture
system the transcriptional effects of 1,25(OH)2D3 at
0.5nM, a concentration that can be safely attained
in vivo, and 100nM, the concentration typically used in
cell culture studies, was compared. In addition, mam-
mary cell lines and fibroblasts obtained from breast can-
cer samples were used to validate transcriptional targets
of 1,25(OH)2D3 in epithelial and stromal cell types.
Cancer associated fibroblasts (CAF) are interactive cells
that infiltrate tumor specimens, influencing their behav-
ior [36-38], which are also potential targets of the hor-
mone. Although VDRs have been detected in fibroblasts
obtained from prostate and breast tumors, few studies
have compared 1,25(OH)2D3 mediated genomic effects
in epithelial and stromal cells [39,40]. The present study
indicates that physiologically relevant concentrations of
1,25(OH)2D3 may influence gene expression in breast
tumor slices cultured ex vivo, and that regulation of
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target genes likely occurs in both epithelial and stromal
compartments of the tumor.
Methods
Patients
Post-menopausal breast cancer patients clinical stages I-
III were invited to take part in the study. This protocol
was carried out in compliance with the Helsinki Declar-
ation and was approved by the Institutional Ethics Com-
mittee (Comitê de Ética do Instituto Brasileiro de
Controle do Câncer, protocol number 108/2006/7;
Comitê de Ética em Pesquisa do Hospital das Clínicas
da Faculdade de Medicina da Universidade de São Paulo,
protocol number 626/06; Comitê de Ética do Hospital
do Câncer A. C. Camargo, protocol number 1131/08). A
written informed consent was signed by all participants.
Twenty one patients were prospectively accrued at
Instituto Brasileiro de Controle do Câncer and Hospital
do Câncer A. C. Camargo, São Paulo, from August 2007
to September 2009. Characteristics of these patients are
described on Table 1.
Tissue slice preparation and treatment
Tumor fragments were obtained immediately after tumor
resection by the pathologist, who selected an involved area
for this study. Fragments were placed into culture medium
(RPMI 1640 with antibiotics and fungicide) and tissue
slices were prepared using the Krumdieck tissue slicing sys-
tem (Alabama Research and Development Corporation,
Birmingham, AL, USA). Fragment thickness varied be-
tween 400–800 μm. Slices were cultured for 24 hours in 6-
well plates (1 slice/well; 1–3 slices per treatment)
containing 2 mL of culture media, RPMI supplemented
with 10% v/v FBS, antibiotics and 0.001% ethanol (vehicle)
or 1,25(OH)2D3 (Calbiochem, Darmstadt, Germany) 0.5nM
or 100nM (from now on called physiological and supra-
physiological concentrations, respectively). One slice of
each sample was processed by FFPE and hematoxilin-eosin
stained slides revealed that tumor samples contained > 50%
malignant cells.
Fibroblasts primary culture
Primary fibroblast culture was established from tumor
samples obtained from another five post-menopausal pa-
tients, diagnosed with invasive ductal carcinoma (histo-
logical grades II or III, three of them hormone receptor
positive). Tumor samples were cut into small pieces and
fibroblast primary culture was established through the ex-
plant methodology. After three cell passages, mesenchymal
origin of the cells was confirmed by their spindle cell
morphology and positive expression of vimentin [mouse
anti human vimentin monoclonal antibody, clone Vim 3b4
(1:200); DAKO Corporation, Carpinteria, CA, USA] and
alpha smooth muscle actin [(mouse monoclonal antibody
anti human alpha smooth muscle actin, clone 1A4 (1:50);
R&D Systems] and negative expression of cytokeratin
[mouse monoclonal antibody anti human cytokeratin clone
AE1/AE3 (1:100); DAKO] by immunocytochemistry (data
not shown). Fibroblasts were then exposed to 1,25(OH)2D3
(Calbiochem, Darmstadt, Germany) 0.5nM or vehicle for
24 hours and after RNA extraction, RT-qPCR was
performed to evaluate expression of candidate genes.
Culture of mammary epithelial cell lines
HB4A (normal mammary epithelial cell line) and C5.2a
(HB4A transfected with HER2), both donated by Drs.
Mike O’Hare and Alan Mackay, Ludwig Institute for
Cancer Research, London, UK; SKBR3: breast cancer cell
line overexpressing HER2; MDA MB-231: breast cancer
cell line triple negative; and MCF-7: breast cancer cell
line ER(+), acquired from American Type Culture
Colection (Manassas, Virginia, USA), were cultured in
RPMI-1640 supplemented with 10% fetal calf serum
(FCS). After 24 hours, medium was replaced and 1,25
(OH)2D3 0.5 nM (treated cells) or ethanol (control cells)
was added. After 24 hs of treatment, total RNA was iso-
lated using Trizol reagent and used in RT-qPCR.
RNA extraction and microarray hybridization
Tumor specimens were pulverized (Bio-Pulverizer™
BioSpec Products Inc., Oklahoma, USA) under liquid ni-
trogen and total RNA was isolated using RNeasy kit
(Qiagen, Valencia, CA, USA), according to the manufac-
turer’s protocol. RNA integrity was verified in a
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA,
USA) and samples with RNA integrity number ≥ 6.6 were
analyzed. Beginning with 100 ng total RNA, a two-round
linear amplification was carried out, according to
Affymetrix protocol (Two Cycle Target Labeling Kit,
Affymetrix, Santa Clara, CA, USA). Afterwards, biotin-
labeled cRNA was synthesized from double strand cDNA,
using IVT labeling kit (Affymetrix) and 20 μg of
Table 1 Characteristics of patients
Training group (n=5) Validation group (n=16) p
Median age 70 (56–76) 56.5 (49–72) 0.068
CS III 3 (60%) 5 (33%) 0.347
N(+) 3 (60%) 9 (60%) 1.000
IDC 5 (100%) 10 (62%) 0.262
ER(+) 2 (40%) 11 (69%) 0.325
PR(+) 3 (60%) 9 (56%) 1.000
HER2(+) 2 (40%) 5 (31%) 1.000
Tumor samples collected for tissue slices culture. Age in years; CS III: clinical
stage III, AJCC 2002; IDC: invasive ductal carcinoma; N(+): lymph node positive
involvement; ER: estrogen receptor immunoexpression; PR: progesterone
receptor immunoexpression; HER2 immunoexpression (+): 3+/3+; (−): negative;
(+): positive. p: Fisher exact test or Mann Whitney test.
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biotinylated fragmented aRNA was hybridized onto
Human Genome U133 Plus 2.0 GeneChip (Affymetrix
Hybridized arrays were scanned using Affymetrix
GeneChip Scanner 3000 and after visual inspection, im-
ages were subjected to Affymetrix GeneChip Operating
Software (GCOS) analysis to generate report files for
quality control. Data normalization was performed using
the Robust Multi-Array Average (RMA). Samples were
categorized according to treatment in three groups: 1,25
(OH)2D3 0.5nM, 1,25(OH)2D3 100nM and control. To
establish a differential gene expression profile between
vitamin D treated and untreated samples, SAM two class
paired, provided on MEV (MultiExperiment Viewer –
Boston, MA, USA) was used, after selecting 50% of the
genes with the highest standard deviation. False discovery
ratio (FDR) ≤0.10 was considered significant. In addition,
results obtained with FDR≤0.01 are presented. Unsuper-
vised hierarchical clustering based on Euclidean distance
and average linkage was used to verify association patterns.
The reliability of the clustering was assessed by the Boot-
strap technique. Raw data complying with MIAME format
was deposited at the Gene Expression Omnibus (GEO)
data repository (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE27220) accession number GSE27220.
To explore functional enrichment associated with
calcitriol treatment based on Ontologies (GO, Pathway),
Regulome (TFBS, transcription factor binding site)
Pharmacome (Drug-gene associations) among other fea-
tures, differentially expressed genes were subject to sub-
sequent analysis using ToppFun, available on ToppGene
Suite (http://toppgene.cchmc.org/enrichment.jsp) and
were considered significant if P < 0.05 [41].
Gene set enrichment analysis (GSEA) method was
used to identify whether predefined gene sets might as-
sociate with gene expression differences between pheno-
types. In this pairwise comparison, all genes are ranked
based on signal-to-noise ratio and the alternative hy-
pothesis that rank ordering of distinct pathway members
is associated with a specific phenotype is tested [42].
This methodology makes it possible to detect situations
where all genes in a predefined set change in a small but
coordinated way. FDR<0.10 was considered significant.
Real time RT-PCR
Reverse transcription was performed with random
primers and Superscript III (Invitrogen Corporation,
Carlsbad, CA, USA). Quantitative PCR (qPCR) was car-
ried out using specific primers (Additional file 1: Table
S1) and SYBR-green I (Sigma, St. Louis, MO, USA) in a
Rotor-gene system (Corbett Research, Mortlake,
Australia). Relative expression of target genes was calcu-
lated as 2-ΔΔCT, using GAPDH or ACTB as internal con-
trol (as indicated) and the average value of the target
gene in control samples, as reference level.
Western blot
Protein lysates from cell lines were made using RIPA
buffer (1% NP-40, 0.1% SDS, 0.5% Sodium Deoxycholate
in 1 × PBS) supplemented with complete mini protease
inhibitor cocktail tablets (Roche; cat 04693124001).
Afterwards, 50 μg of protein was subjected to SDS-
PAGE and transferred to Hybond ECL membrane (GE
Lifesciences), which was probed with the following pri-
mary antibodies overnight at 4°C: CD26 (DPP4, clone
H-270, rabbit polyclonal antibody, 1:500; Santa Cruz
Biotechonology Inc. Santa Cruz, CA, USA); CD14 (clone
M305, sc9150, rabbit polyclonal antibody 1:500; Santa
Cruz); β-actin (monoclonal Anti-β-Actin antibody pro-
duced in mouse, clone AC-15, ascites fluid, A5441,
1:2000, Sigma-Aldrich) and then with appropriate second-
ary antibodies (170–6515 Goat Anti-Rabbit Ig-G (H+L)
HRP conjugate; 170–6516 Goat Anti-Mouse Ig-G (H+L)
HRP conjugate; Bio-Rad.). Protein expression was
detected with ECL Plus Western Blotting Detection
Reagents (GE Lifesciences) in a ImageQuant LAS 4000
(GE Healthcare).
Immunocytochemistry
Fibroblasts were grown on coverslips in the absence or
presence of 1,25(OH)2D3 0.5nM for 24 hours. Samples
were fixed in 4% paraformaldehyde and permeabilized
with 0.5% Triton X-100/PBS, in case of intracellular tar-
gets. Blocking of unspecific binding was performed with
2% BSA/PBS. Afterwards, cells were incubated with the
primary antibody (CD26, clone H-270 rabbit polyclonal
antibody, anti-DPP4, 1:200, Santa Cruz; CA II, clone G-2,
sc-48351 mouse monoclonal antibody, 1:100, Santa Cruz)
overnight in humid chamber at 4°C and then with the
secondary antibody conjugated with Alexa Fluor 488
(1:700, species specific: goat anti-rabbit IgG, n° A11008;
goat anti-mouse IgG n° A11001; Molecular Probes) for
1 h at room temperature in the dark. DAPI was added for
nuclear staining. Images were acquired in a Olympus
fluorescence microscope DX-5AI, using an Image Pro-
PLUS 6,0 software.
Immunohystochemistry
Breast cancer slices from seven patients (six samples cul-
tured in the absence (control) or presence of 1,25(OH)
2D3 100nM and one sample cultured in the presence of
1,25(OH)2D3 0.5nM) were available for analysis (from
the patients described in Table 1). Sections of 3 μm
thickness were cut from paraffin blocks and antigen re-
trieval was carried out in 10 mM citrate buffer at pH 6.0
in humid heat under pressure cooker. Staining with the
following specific antibody took place overnight at 4°C:
CD14, clone M-305, (sc-9150Santa Cruz Biotechnology)
rabbit polyclonal IgG, 1:800. Reaction was revealed with
Novolink Polymer Detection Systems (Leica Biosystems,
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Newcastle, UK, cat: RE7280-k), followed by analysis in a
Olympus fluorescence microscope DX-5AI (40x object-
ive) and acquisition with an Image Pro-PLUS 6,0
software.
Detection of soluble CD14 (sCD14) in culture medium of
tumor samples
Tumor slices from another four post-menopausal patients
(median age 56 years) diagnosed with invasive ductal car-
cinoma clinical stages I-II, HER2 negative and hormone
receptor positive (except for one tumor triple negative)
were cultured with or without 1,25(OH)2D3 0.5nM or
100nM for 24 hours and 100 μL of the conditioned
medium was used for soluble CD14 (sCD14) quantitative
determination, through an enzyme-linked immunosorbent
assay (Quantikine ELISA Human sCD14 Immunoassay,
R&D Systems, Minneapolis, MN, USA). For every sample,
two analyses on the same plate were carried out and the
mean value was used.
Statistics
Kolmogorov-Smirnov test was applied to check for nor-
mality of the data, followed by parametric or non-
parametric tests, as appropriate. To detect an association
between variables, Pearson chi-square or Fisher exact
tests were used. A two-tailed p value ≤ 0.05 was consid-
ered significant. Analysis was undertaken using Instat
(GraphPad Software, Inc., La Jolla, CA, USA) or SPSS
(Chicago, IL, USA).
Results
Patients characteristics
Twenty one post-menopausal patients with breast cancer
clinical stages I-III were included in this study. Samples
from five patients were analyzed in a training group,
using microarray, and from another 16 patients were an-
alyzed in a validation group, using RT-qPCR. There were
no differences between groups concerning age, clinical
stage, lymph node involvement; ductal histology; ER, PR
and HER2 immunoexpression (Table 1).
Vitamin D transcriptional effects in breast cancer slices
At first, the transcriptional effects of 0.5 nM 1,25(OH)
2D3 vs control in breast cancer slices were compared,
using SAM paired analysis (FDR ≤ 0.1). As shown in
Table 2, seven genes were up-regulated and two genes
were down-regulated in tumor slices exposed to 0.5nM
1,25(OH)2D3 for 24 h. Enrichment of genes involved in
vitamin metabolic process (TKTL1, CYP24A1, CYP26B1)
was observed. Unsupervised clustering of the differen-
tially expressed genes identified two branches, however
there was no aggregation of samples according to 1,25
(OH)2D3. treatment (Figure 1). At a more stringent FDR
level (≤ 0.01), only five (CYP24A1, DPP4, EFTUD1,
FCGR2C, SAMSN1) genes were differentially expressed.
Using GSEA (motif, transcription factors), to compare
samples treated with 0.5nM 1,25(OH)2D3 treated and
untreated, only one gene set was enriched at FDR ≤ 0.1,
namely DR3, comprising genes containing a motif for
vitamin D receptor (VDR) around the transcription start
site (Additional file 2: Table S2).
Next, the effects of a 24 h exposure to 1,25(OH)2D3
100nM was evaluated in this model system. Using FDR
cut offs of ≤ 0.1 and ≤ 0.01, 196 (136 more and 60 less
expressed in treated samples) and 30 (28 more and 2 less
expressed in treated samples) candidate target genes
were found, respectively (Additional file 3: Table S3).
Up-regulated genes were involved in vitamin metabolic
process, regulation of leukocyte mediated immunity and
positive regulation of alpha-beta T cell activation. In
addition, some genes were associated with calcitriol and
TGF-beta signaling pathway (Table 3). There was no
separation of treated and untreated samples, upon un-
supervised hierarchical cluster analysis, and paired tu-
mors co-aggregated in the same branch (Additional file
4: Figure S1).
Table 2 Genes differentially modulated in breast tumor slices incubated with 0.5nM 1,25(OH)2D3
Gene title Gene symbol FC
cytochrome P450, family 24, subfamily A, polypeptide 1 CYP24A1 7.54
dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2) DPP4 2.01
cytochrome P450, family 26, subfamily B, polypeptide 1 CYP26B1 1.94
potassium channel, subfamily K, member 3 KCNK3 1.92
transketolase-like 1 TKTL1 1.55
spindlin family, member 3 SPIN3 1.55
elongation factor Tu GTP binding domain containing 1 EFTUD1 1.49
Fc fragment of IgG, low affinity IIc, receptor for (CD32) FCGR2C −1.61
SAM domain, SH3 domain and nuclear localization signals 1 SAMSN1 −1.79
SAM paired analysis FDR ≤ 0.10 (FDR ≤ 0.01, genes marked in bold). FC: Fold change of the ratio. (−): lower expression in 1,25(OH)2D3 treated (as compared with
untreated) samples.
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To determine overlapping genes up-regulated by both
calcitriol concentrations (at FDR ≤ 0.1), a Venn diagram
was assembled. This approach identified five commonly
up-modulated genes: CYP24A1, DPP4, EFTUD1, TKTL1
and KCNK3.
The reproducibility of the present gene list was further
tested against gene lists determined in other cell lines.
To this end, vitamin D (100 nM) up-regulated genes
were cross checked in breast cancer slices and derived fi-
broblasts [40], squamous carcinoma [43] immortalized
Figure 1 Unsupervised hierarchical clustering of breast cancer slices exposed to vehicle or 0.5nM 1,25(OH)2D3. Five tumor samples (6,
11, 12, 13, 15) were cultured with or without 0.5nM 1,25(OH)2D3 for 24 h. Gene expression was evaluated by microarray and analysis performed
using SAM paired analysis (FDR ≤ 0.1). The upper colored bar and values indicate gene expression in target samples (i.e., red, more expressed and
green, less expressed). Colored lines of the dendrogram and numbers stand for the support for each clustering, black and gray, more reliable;
yellow and red, less reliable. Nine genes were differentially expressed (plus one probe without a gene name, NA). Two branches are identified,
one of them including three control samples.
Table 3 Functional categories of genes up-regulated in breast tumor slices incubated in 100 nM 1,25(OH)2D3
Genes up-regulated in VD3 100nM treated samples
Biological process
Response to external stimulus TGFBR2, LXN, THBD,PTEN, PTGER3, HBEGF, CYP24A1, ACVRL1, CCL19, FOXF1, FYN, OSM, CD28, CD14, BMP6, BMP2,
PLAT, CD1D, PKD2, SERPINA1, PROCR, ALDH1A2
Response to wounding TGFBR2, THBD, PTGER3, HBEGF, ACVRL1, CCL19, FOXF1, OSM, CD28, CD14, BMP6, BMP2, PLAT, SERPINA1, PROCR
Regulation of leukocyte mediated
immunity
CD226, FOXF1, DPP4, CD28, CD1D, GIMAP1
Pathway-restricted SMAD protein
phosphorylation
TGFBR2, ACVR1B, BMP6, BMP2
Urogenital system development CRLF1, PTEN, CYP19A1, BMP6, BMP2, CA2, PKD2, ALDH1A2
Vitamin metabolic process TKTL1, SLC22A4, CYP24A1, DHRS9, MTAP, PSAT1, ALDH1A2
Positive regulation of alpha-beta T
cell activation
TGFBR2, CD28, CD1D, GIMAP1
KEGG pathway
TGF-beta signaling pathway TGFBR2, ACVRL1, ACVR1B, IDA, BMP6, BMP2
Drugs
Calcitriol EFTUD1, EHBP1, TRIM56, HBEGF, CYP24A1, CYP19A1, ACVRL1, ACVR1B, SEMAD6D, ARRDC4, CD14, BMP6, PRKD1,
BMP2, CLMN, PLAT, IL1RL1, PRKCH, SLC1A1, CA2, FAM20C, SHE
(Toppgene, p<0.05).
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prostate [44], and lymphoblastoid cell lines [45] as well
as in carotid artery smooth muscle cells [46] (Figure 2).
These cell lines were treated with supra-physiological
concentrations, ranging from 10-100nM, of 1,25(OH)
2D3 or EB1089 (vitamin D analog) for 12–36 hours.
This analysis revealed CYP24A1 as the universal vitamin
D target gene in all cell types. Expression of CLMN,
EFTUD1 and SERPINB1 was up-regulated in five of the
six studies and BMP6, CD14, FAM20C, and THBD in
four studies. CA2, CILP, CYP19A1, DCBLD1, DPP4,
FOXF1, G0S2, GRK5, IL1RL1, KCNK3, SEMA6D and
SLC1A1 were up-regulated in another two studies, in
addition to the present one. Many of these genes were
also regulated by vitamin D in this organotypic culture.
A subset of seven genes was selected for further ana-
lysis in samples from another group of patients, using
qPCR. Candidates were chosen from microarray analysis
and included two genes modulated by both calcitriol
concentrations: CYP24A1 and DPP4; and five genes reg-
ulated by 100nM calcitriol at a fold change > 2, com-
pared to control samples: IL1RL1, SHE, CD14, CA2 and
BMP6. Initially, significant correlations between gene ex-
pression values obtained from the microarray dataset
and those obtained by subsequent qPCR analysis in the
first group of five patients were evaluated, as a technical
validation procedure. In these 15 samples (control; 0.5nM
1,25(OH)2D3 and 100nM 1,25(OH)2D3) significant direct
correlations were demonstrated for all genes, except for
BMP6 (Additional file 5: Table S4).
Subsequently, the expression of these seven genes was
determined in samples from an additional group of 16 pa-
tients (validation subset). In these samples, CYP24A1,
DPP4 and CA2 were up-regulated by both 1,25(OH)2D3
0.5 and 100nM whereas CD14 expression was induced
only by 1,25(OH)2D3 100nM (Figure 3). Median expres-
sion of IL1RL1, SHE, and BMP6 was not significantly up-
regulated by either dose of 1,25(OH)2D3 in these add-
itional samples, even though elevated mRNA levels were
detected in a subset of tumors after treatment.
Vitamin D transcriptional effects in epithelial and stromal
cells
The effects of 1,25(OH)2D3 0.5nM on the expression of
CYP24A1, DPP4, IL1RL1, CD14, CA2 and BMP6, were
further explored in breast tumor derived cells, representing
the epithelial and stromal compartments, using RT-qPCR.
For this analysis, normal and cancerous breast cell lines
(HB4A, C5.4, SKBR3, MDA-MB231, MCF-7) and cancer
associated fibroblasts (primary cultures obtained from
fresh tumor samples) were used. In the breast-derived epi-
thelial cell lines, robust expression of CYP24A1 was ob-
served in all lineages, indicating functional VDR expression.
Breast cell lines (HB4a, C5.4, SKBR3) that exhibited low
baseline CYP24A1 expression showed larger fold-induction
Figure 2 Overlapping genes up-regulated by 1,25(OH)2D3 10-100nM in cell lines. Venn diagram of 1,25(OH)2D3 up-regulated genes in
breast cancer slices (A) cancer associated fibroblasts and normal adjacent fibroblasts (B) [40]; non-transformed prostate epithelial cell line (C) [44];
human coronary artery smooth muscle cells (D) [46]; SCC25 cells (floor of the mouth/base of the tongue squamous tumor, (E) [43] and
lymphoblastoid cell lines (F) [45]. B, C, and D include non-transformed cells. Number of genes regulated in two cell lines appears on the diagram;
number of genes regulated in more than two cell lines appears on the text.
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Figure 3 Effect of 1,25(OH)2D3 on expression of CYP24A1, CA2, CD14, DPP4, SHE, BMP6 and ILRL1 in breast cancer slices. Tumor
specimens from 12–16 patients were treated or not (control) with 1,25(OH)2D3 (0.5nM or 100nM) for 24 hours and analyzed by qPCR. Relative
expression was calculated as 2-ΔΔCT, using GAPDH as internal control and the average value of the target gene in control samples, as reference.
Horizontal line represents the median value of gene expression. Friedman test, p value inside the box; * (over the horizontal bracket): p ≤ 0.05,
Wilcoxon signed ranks test.
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of this gene than cell lines (MCF-7, MD-MBA-231)
presenting high baseline CYP24A1. Expression of
CA2, CD14 and IL1RL1, was significantly induced by
1,25(OH)2D3 0.5nM, but considerable variability in
the response of individual lineages was observed, and
cells displaying the most robust up-regulation of
CYP24A1 in response to 1,25(OH)2D3 did not neces-
sarily exhibit the highest induction of the other target
genes. Three of the breast cancer cell lines de-
monstrated up-regulation of BMP6 in response to
Figure 4 Effect of 0.5nM 1,25(OH)2D3 on expression of CYP24A1, CD14, CA2, DPP4, ILRL1 and BMP6 in cancer infiltrating fibroblasts and
mammary epithelial cells. Cancer infiltrating fibroblasts (n=5) and breast derived cell lines (left to right: HB4A, C5.4, SKBR3, MCF7, MDA-MB231)
were cultured in the presence or absence of 0.5nM 1,25(OH)2D3 for 24 h. Three independent assays for each cell line were performed and the
mean relative gene expression value was calculated. Gene expression was determined by RT-qPCR and relative expression is shown on the Y axis
(which is in log scale for CYP24A1, CA2, CD14, DPP4 and IL1RL1). p values: Wilcoxon signed ranks test. White bar: control samples; Gray bars: 1,25
(OH)2D3 treated samples.
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1,25(OH)2D3 0.5nM however, the group response was
not statistically significant.
In five independently-derived primary cultures of
cancer-associated fibroblasts, CYP24A1 expression was
consistently induced in response to 1,25(OH)2D3 0.5nM
indicating active VDR signaling in the tumor stroma.
However, none of the other target genes, identified
in the microarray analysis, were significantly up-
regulated in tumor fibroblasts cultured with 0.5nM
1,25(OH)2D3 ex vivo , even though there was a trend
towards up-regulation of CA2, IL1RL1 and DPP4
(Figure 4).
Vitamin D effects on protein expression
Vitamin D effects in protein expression were analyzed in
tumor slices and culture medium, as well as in epithelial
cell lines and fibroblasts.
Tumor slices from seven patients (in FFPE, six samples
cultured in the absence or presence of 1,25(OH)2D3
100nM and one sample in the presence of 1,25(OH)2D3
0.5nM) were available for immunohistochemistry. CD14
moderate cytoplasmic staining was observed in at least
50% of tumor cells and weak staining of 10% of the fibro-
blasts. No differences could be detected between 1,25
(OH)2D3 treated and untreated tumor samples (Figure 5).
CD14 may be either soluble (sCD14) or membrane-
bound (mCD14). There is evidence that sCD14 may be
detected in plasma samples from breast cancer patients,
hence we determined whether sCD14 concentration
might be regulated in the culture medium of breast can-
cer slices. Although no significant statistical differences
were found between control and calcitriol treated sam-
ples (0.5nM and 100nM), there was a trend towards
higher values of sCD14 in 3/4 samples exposed to 1,25
(OH)2D3 100nM (Figure 6).
In mammary epithelial cell lines and cancer associated
fibroblasts protein expression was analyzed through
western blot and immunocytochemistry. CD14 was more
expressed in MCF7 and C5.2 treated with 0.5nM 1,25
(OH)2D3, as compared with untreated cells, however no
differences in CD14 expression were observed in fibro-
blasts exposed to 1,25(OH)2D3. In MCF7 cells, DPP4
(CD26) expression was also induced after 1,25(OH)2D3
0.5nM exposure (Figure 7). In addition, in fibroblasts,
CA2 as well as DPP4 cytoplasmic immunoexpression
was more intense in 1,25(OH)2D3 treated than in control
cells (Figure 8).
Figure 5 CD14 expression in breast cancer samples. Tumor slices were cultured in the absence (control: B, E) or presence of 1,25(OH)2D3
100nM (C) or 0.5nM (F) for 24 h. Protein expression was examined by immunohistochemistry. CD14 expression was detected as a cytoplasmic
staining. Negative reaction with secondary antibodies exclusively, appears on the left (A, D). scale bar: 25μm.
Figure 6 Soluble CD14 in the conditioned medium of breast
cancer slices. Tumor specimens from four patients with invasive
ductal carcinoma (not included in previous analysis of microarray or
PCR) were cultured with or without (control, white bars) 1,25(OH)2D3
0.5 (hatched bars) or 100 nM (gray bars) for 24 h. sCD14
concentration was evaluated in the conditioned medium by ELISA
(p=0.42; Friedman’s test).
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Discussion
The primary goal of this work was to evaluate the tran-
scriptional responses of breast cancer samples to physio-
logically relevant concentrations of 1,25(OH)2D3, using a
culture model that retains features of intact tumors,
such as stromal-epithelial interactions. Microarray ana-
lysis identified nine genes that were significantly altered
within 24 h of exposure to 1,25(OH)2D3 0.5nM, a con-
centration that is physiologically achievable in patients.
Of these, the vitamin D target gene CYP24A1(which
codes a cytochrome P450 enzyme, that hydroxylates 25
(OH)D3 and 1,25(OH)2D3 to less active forms 24,25
(OH)2D3 and 1,24,25(OH)3D3) was induced over 7-fold
in microarray analysis and was validated in another set
of tumor samples, clearly indicating activation of VDR
signaling. Additional evidence for activation of the VDR
pathway in this dataset was obtained by GSEA, which
indicated a trend towards the enrichment of genes shar-
ing DR3 binding sites, a consensus motif for VDR.
Comparison of microarray data from tumor slices cul-
tured with 0.5nM vs. 100nM 1,25(OH)2D3 indicated a
clear concentration effect, as the number of differentially
expressed transcripts increased from nine at 0.5nM to
186 at 100nM (20 fold increment). Induction of CYP24A1
increased from 7-fold (at 0.5 nM) to 70-fold (at 100nM) -
a 10 fold enhancement. In both datasets, the majority of
genes (approximately 75%) were up-regulated rather than
down-regulated by 1,25(OH)2D3, consistent with other
array data from established cell lines cultured with high
dose 1,25(OH)2D3 in vitro [43-45].
In addition to CYP24A1, five other genes were com-
monly up-regulated in tumor slices exposed to both low
and high concentrations of 1,25(OH)2D3: DPP4, KCKN3,
EFTUD1, TKTL1 and CA2. All, except TKTL1 (trans-
ketolase-like 1) have been previously identified as VDR
target genes in various model systems. DPP4 (dipeptidyl-
peptidase 4, also called CD26) was up-regulated in artery
smooth muscle cells exposed to 1,25(OH)2D3 [46] and
its overexpression in distinct cell types (melanocytes,
non-small cell lung, prostate and neuroblastoma cells)
triggered anti-tumorigenic effects including cell growth
arrest, inhibition of cell migration and increased apoptosis
[47]. KCNK3 (potassium channel, subfamily K, member)
was induced by 1,25(OH)2D3 in artery smooth muscle
cells, and EFTUD1 (elongation factor Tu GTP binding do-
main containing 1) in oral squamous carcinoma, breast
cancer associated fibroblasts, immortalized prostate cells
and lymphoblastoid cell lines [40,43-46]. CA2 (carbonic
anhydrase II) mRNA appeared to be directly induced by
1,25(OH)2D3 in myelomonocytic cell lines but indirectly
regulated in osteoclast progenitors, where the physical
communication with stromal cells seems to be required
[48,49]. CYP26B1 (cytochrome P450, family 26, subfamily
b, polypeptide 1) which was up-regulated in samples
treated with 1,25(OH)2D3 0.5nM, was previously identified
as a vitamin D induced gene in immortalized non-
transformed prostate epithelial and oral squamous carcin-
oma cell lines, and in silico analysis has tentatively identi-
fied a VDR binding site at this genomic region [43,44].
Other authors have analyzed physiological concentra-
tion effects of vitamin D using animal models. Vitamin
D supplemented diet as well as calcitriol injections were
shown to stimulate the VDR pathway, mildly increasing
CYP24A1 expression (x2) in MCF-7 xenografts in im-
munocompromised mice [50]. Interestingly, vitamin D
transcriptional effects may not overlap in tumor speci-
mens and non-transformed mammary glands in the
MMTV-neu transgenic mouse model of breast cancer,
fed a high vitamin D diet [51]. Comparison between can-
cer and normal cells is an interesting issue, as vitamin D
potential effects in cancer prevention have also been
claimed. In accordance with the previous work [51], dif-
ferences in transcriptional targets were also described
for breast cancer associated fibroblasts (CAF) and nor-
mal adjacent fibroblasts (NAF) exposed to 1,25(OH)2D3
in a supra-physiological concentration. Among up-
regulated genes 45.7% were commonly modulated in
CAFs and NAFs, however, 36.4% were exclusively up-
regulated in NAFs and 17.4% exclusively up-regulated in
CAFs [40]. In addition, looking at overlapping genes in
the Venn diagram of vitamin D up-regulated transcripts
in six works [40,43-46], only seven intersections were
found in non-cancer cells: AKR1B1, CRIP1, FZD8, MREG
(in immortalized prostate cells and NAF), BCAT1, GCLC
Figure 7 CD14 and DPP4 (CD26) expression in mammary epithelial cell lines and fibroblasts. MCF7 and C5.2 cells as well as fibroblasts
were cultured in the absence (control, C) or presence of 1,25(OH)2D3 0.5 nM (D 0.5). Protein expression was analyzed through western blot. Two
assays were performed with similar results.
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(in coronary artery smooth muscle cells and NAFs) and
PRR6 (in immortalized prostate cells and coronary artery
smooth muscle cells). Furthermore, it was reported that
vitamin D response is blunted in transformed HME nor-
mal mammary cells as compared with parental normal
cells [52]. The last works evaluating vitamin D effects in
normal cells however, were performed using supra-
physiological concentrations of 1,25(OH)2D3 (10-100nM)
or analogs and the role of physiological concentrations of
the hormone in normal cells is not fully established.
At 100nM, 1,25(OH)2D3 exerted more extensive tran-
scriptional effects, and at least 40 of the induced genes in
breast cancer organotypic culture have already been
reported as up regulated by the hormone, such as ALCAM,
ARRDC4, BMP2, BMP6, CA2, CD14, CLIC6, CILP, CLMN,
CYP19A1, DCLDB1, EFTUD1, EHBP1, FAM20C, FOXF1,
FRAS1, GOS2, GRK5, HBGEF, HSMPP8, IL1RL1, KCNK3,
KIAA0500, PKD2, RGNEF, SEMA6D, SERPINB1, SLC1A1,
THBD, TIMP1, TRIM56 [40,43-46]. However, co-
aggregation of paired samples (treated and untreated)
upon cluster analysis suggests that an individual dominant
transcriptional profile was maintained, regardless of treat-
ment. These results were not unexpected, as a high degree
of transcriptional similarity was also demonstrated for
matched pre and post-neoadjuvant chemotherapy, even
though the chemotherapy exerts a more pronounced
acute cellular effect than hormonal treatments [53-55].
Some of the genes induced by 100nM 1,25(OH)2D3 con-
centration are involved in TGF beta signaling pathway, in
accordance with other authors [56,57]. Other genes are in-
volved in regulation of leukocyte mediated immunity and
positive regulation of alpha-beta T cell activation, includ-
ing CD14, which encodes a receptor to bacterial lipopoly-
saccharide, as previously reported in a variety of cells
as mononuclear phagocytes, normal human epidermal
keratinocytes, oral squamous carcinoma, immortalized
non-transformed prostate epithelial cell lines and ma-
lignant breast cells [43,56,58].
The present tumor slice model represents a heteroge-
neous combination of epithelial and stromal cells, in
which the complex array of reciprocal interactions taking
place in the tumor microenvironment, including cell-cell
contacts and a variety of secreted factors, might modulate
the overall response to 1,25(OH)2D3. Hence, after evaluat-
ing the hormone effects in tumor slices, the effects of 1,25
(OH)2D3 0.5nM in defined populations of cancer associ-
ated fibroblasts and epithelial cells were compared. This
data indicated that even though CYP24A1 was induced in
both fibroblasts and epithelial cells, CD14, CA2, and
IL1RL1 were primarily induced in epithelial cells. There
was also a trend towards up-regulation of CA2, DPP4 and
IL1RL1 in cancer associated fibroblasts.
One major strengthen of this work was the compari-
son of achievable versus supra-physiological concentra-
tions of 1,25(OH)2D3 in breast cancer slices, a model
that preserves the epithelial-mesenchimal interactionss,
indicating that effects are much less intense in near
physiological concentrations. However, a weakness of
this work was the small number of samples used in
microarray experiments. These effects however, were
later confirmed in a larger number of tumor samples
and cell lines, using RT-PCR, even though they were
more difficult to detect at the protein level, in face of
the discrete changes induced by 0.5nM 1,25(OH)2D3.
Conclusion
Our main conclusion is that a very modest transcriptional
response may be observed after exposure to 1,25(OH)2D3,
within the physiological concentration range. Gene targets
in breast cancer samples, including CYP24A1, DPP4
and CA2, seem to be shared by both fibroblasts and
epithelial cells. A higher number of genes may be in-
duced by a supra-physiological concentration of the
hormone. Further studies employing physiological and
supra-physiological concentrations may help to elucidate
the hormone’s potential effects in breast cancer prevention
and treatment, including calcitriol supplementation effects
in post-menopausal women and calcitriol intra-tumoral
effects in breast cancer xenografts.
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